Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028)

Microbiology and Immunology

Volumn 45, Issue 7, 2001, Pages 531-537

  Sudo, Kenji ^a   Konno, Kenji ^a   Watanabe, Wataru ^a   Shigeta, Shiro ^b   Yokota, Tomoyuki ^a  

^a Rational Drug Design Laboratories   (Japan)

^b FUKUSHIMA UNIVERSITY   (Japan)

Author keywords

F1 protein; RD3 0028; Resistant viruses; Respiratory syncytial virus

Indexed keywords

1,4 DIHYDRO 2,3 BENZODITHIIN; ANTIVIRUS AGENT; ASPARAGINE; RD3 0028; RIBAVIRIN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; GENE SEQUENCE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INFLUENZA VIRUS A; MEASLES VIRUS; PROTEIN PROCESSING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STRAIN DIFFERENCE; SYNCYTIUM; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 5; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VIRUS; MEASLES VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES; SYNCYTIAL VIRUS;

EID: 0034912960     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2001.tb02654.x     Document Type: Article

References (28)

1. Targeting RNA decay with 2′,5′-oligoadenylate-antisense in respiratory syncytial virus-infected cells
2. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus
3. Use of ribavirin in the treatment of respiratory syncytial virus infection
4. Recombinant human respiratory syncytial virus (RSV) monoclonal anti-body Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice
5. Kinetics of synthesis of respiratory syncytial virus glycoproteins
6. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics
7. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
8. Respiratory syncytial virus polypeptides. V. The kinetics of glycoprotein synthesis
9. Prospects for a respiratory syncytial virus vaccine
10. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection
11. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic polymers interacting with virus-cell binding and/or fusion
12. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion
13. Conformational changes in Newcastle disease virus fusion glycoprotein during intracellular transport
14. Conformational changes in a viral glycoprotein during maturation due to disulfide bond disruption
15. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
16. Progress towards control of the acute respiratory viral diseases of childhood
17. Antiviral activities of peptides with sequences related to the cytoplasmic domain of the respiratory syncytial virus glycoproteins
18. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants with bronchopulmonary dysplasia
19. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses
20. In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates
21. New neplanocin analogues. 1. Synthesis of 6′-modified neplanocin A derivatives as broad-spectrum antiviral agents
22. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus
23. Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice
24. Monoclonal antibodies protect against respiratory syncytial virus infection in mice
25. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies
26. Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies
27. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents
28. Novel anti-respiratory syncytial (RS) viral compounds: Benzodithiin derivatives